Cargando…

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma

Tirabrutinib (TIR), a Burton’s tyrosine kinase inhibitory drug, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refractory PCNSL using TIR. Three patients, 48, 78 and 88...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onodera, Sho, Akimoto, Jiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648228/ http://dx.doi.org/10.1093/noajnl/vdab159.093

Ejemplares similares

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

ML-18 Clinical diagnosis for suspected primary central nervous system lymphoma patients without histopathological confirmation
por: Osawa, Sho, et al.
Publicado: (2020)

ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution
por: Kuwahara, Kiyonori, et al.
Publicado: (2020)

ML-01 Pathological characteristics of primary central nervous system lymphoma with atypical radiological finding
por: Inukai, Madoka, et al.
Publicado: (2020)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-13 Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab
por: Ohno, Masasuke, et al.
Publicado: (2021)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
por: Okita, Yoshiko, et al.
Publicado: (2021)

ML-3 A Case of Primary Central Nervous System Anaplastic Lymphoma Kinase Positive Anaplastic Large cell Lymphoma at Neurohypophysis and Pineal Gland
por: Kohno, Shohei, et al.
Publicado: (2021)

ML-4 A case of primary CNS lymphoma diagnosed 5 years after stereotactic radiosurgery
por: Tabei, Yusuke, et al.
Publicado: (2021)

Recovery from coma of a patient having acute progression of primary central nervous system lymphoma using tirabrutinib and methylprednisolone
por: Satow, Takeshi, et al.
Publicado: (2020)

Advances in the treatment of newly diagnosed primary central nervous system lymphomas
por: Qian, Liren, et al.
Publicado: (2017)

Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective
por: Thomas, Alice, et al.
Publicado: (2023)

SS-5 Current management of primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

COT-20 Clinical experience with tumor-treating fields therapy for newly diagnosed glioblastoma
por: Saito, Norihiko, et al.
Publicado: (2020)

ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid
por: Yamagishi, Yuki, et al.
Publicado: (2020)

ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma
por: Yuki, Yamagishi, et al.
Publicado: (2021)

ML-09 DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN HIV POSITIVE PATIENTS
por: Takano, Koji, et al.
Publicado: (2019)

TB-6 Experimental evaluation of the therapeutic potential of boron neutron capture therapy in primary central nervous system lymphoma
por: Yoshimura, Kohei, et al.
Publicado: (2021)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
por: Kuhlman, Justin J, et al.
Publicado: (2022)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma
por: Tateishi, Kensuke, et al.
Publicado: (2020)

COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2020)

ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Nagane, Motoo, et al.
Publicado: (2019)

ML-05 A CASE OF NEUROLYMPHOMATOSIS ARISED SECONDARILY FROM PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Horiguchi, Keishi, et al.
Publicado: (2019)

Bing-Neel Syndrome Successfully Treated with Tirabrutinib
por: Oyama, Takashi, et al.
Publicado: (2022)

Rare central nervous system tumors: the path to progress
por: Penas-Prado, Marta
Publicado: (2021)

The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
por: Zheng, Xiaohong, et al.
Publicado: (2020)

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib
por: Sekiguchi, Yasunobu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dtsdskqu7mcrcb1ub0gaavkd4l